October 19-23 2022. Dr. Oliver Bathe presented results from a study of 742 patients at the 2022 Annual Meeting of the American Thyroid Association. The study demonstrated that Thyroid GuidePx® has a 97% specificity in identifying patients with low-risk papillary thyroid cancer. This is much more accurate than the 80% specificity the conventional ATA risk stratification system identifies.

Thyroid GuidePx® identifies features in papillary thyroid cancers that will provide thyroid surgeons and endocrinologists with greater insight into any patient’s tumor biology.

This study was a collaboration between the University of Calgary (Canada), the University of Wollongong (Australia) and Seoul National University (Korea).